Abstract

Cutaneous immune-related adverse events (cirAEs) occur in up to 40% of immune checkpoint inhibitor (ICI) recipients. However, the association of cirAEs with survival remains unclear. To investigate the association of cirAEs with survival among ICI recipients. ICI recipients were identified from the Mass General Brigham healthcare system and Dana-Farber Cancer Institute. Patient charts were reviewed for cirAE development within 2years after ICI initiation. Multivariate time-varying Cox proportional hazards models, adjusted for age, sex, race/ethnicity, Charlson Comorbidity Index, ICI type, cancer type, and year of ICI initiation were utilized to investigate the impact of cirAE development on overall survival. Of the 3731 ICI recipients, 18.1% developed a cirAE. Six-month landmark analysis and time-varying Cox proportional hazards models demonstrated that patients who developed cirAEs were associated with decreased mortality (hazardratio [HR]=0.87, P=.027), particularly in patients with melanoma (HR=0.67, P=.003). Among individual morphologies, lichenoid eruption (HR=0.51, P<.001), psoriasiform eruption (HR=0.52, P=.005), vitiligo (HR=0.29, P=.007), isolated pruritus without visible manifestation of rash (HR=0.71, P=.007), acneiform eruption (HR=0.34, P=.025), and non-specific rash (HR=0.68, P<.001) were significantly associated with better survival after multiple comparisons adjustment. Retrospective design; single geography. CirAE development is associated with improved survival among ICI recipients, especially patients with melanoma.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.